BioCryst to Present at Upcoming Investor Conferences

Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) announced its participation in two upcoming healthcare conferences. The company will present at the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 11:35 a.m. ET, and will also take part in the H.C. Wainwright 24th Annual Global Investment Conference. A pre-recorded fireside chat for this latter event will be available on September 12, 2022, at 7:00 a.m. ET. Links to live webcasts and replays will be accessible on BioCryst's website.

RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022 at 11:35 a.m. ET and the H.C. Wainwright 24^th Annual Global Investment Conference. A pre-recorded fireside chat for the H.C. Wainwright conference will be made available Monday, September 12, 2022, at 7:00 a.m. ET.

Links to live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States and multiple global markets. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and yellow fever. RAPIVAB^® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

FAQ

What is the schedule for BioCryst Pharmaceuticals' conference presentations?

BioCryst Pharmaceuticals will present at the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 11:35 a.m. ET, and at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.

Where can I watch the presentations by BioCryst Pharmaceuticals?

Live audio webcasts and replays of BioCryst Pharmaceuticals' presentations can be accessed in the Investors & Media section of their website.

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals is traded under the stock symbol BCRX.

What are some products developed by BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals has developed ORLADEYO® (berotralstat) for treating rare diseases and has ongoing programs such as BCX9930 and galidesivir.